US FDA gives Protalix's Gaucher's drug temporary approval to fill shortage
This article was originally published in Scrip
Executive Summary
The US FDA has approved a treatment protocol for Protalix Biotherapeutics' Gaucher's disease drug prGCD, enabling doctors to get the recombinant plant-cell expressed enzyme replacement therapy to patients before its formal approval and commercialisation. The company's share price rose by 11%, to close at $6.39, on AMEX on August 17th.